Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Beckman Coulter Diagnostics earns CE mark for new assay delivering bacterial vs viral infection results in approximately 20 minutes

13

Apr 2026

Beckman Coulter Diagnostics earns CE mark for new assay delivering bacterial vs viral infection results in approximately 20 minutes

Beckman Coulter Diagnostics, a Danaher company and global leader in clinical diagnostics, today announced it has received CE 2797 mark under IVDR for the Access MeMed BV assay, enabling broad availability of a high-throughput host‑response test that helps clinicians differentiate between bacterial and viral infections in approximately 20 minutes.

Obesity health risks differ significantly between men and women

13

Apr 2026

Obesity health risks differ significantly between men and women

New research being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May), reveals distinct patterns of heart, metabolic, and inflammatory health risks between men and women living with obesity, providing an insight into how clinicians may be able to tailor management approaches.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.